PAPER Lee J, Culyba EK, Powers ET, Kelly JW

Amyloid-β forms fibrils by nucleated conformational conversion of oligomers.

Nat Chem Biol. 2011 Sep;7(9):602-9. PubMed: 21804535

PAPER Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, Jack CR, Jagust W, Decarli C, Toga AW, Toledo E, Xie SX, Lee VM, Trojanowski JQ, Shaw LM,

Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI.

Acta Neuropathol. 2011 Oct;122(4):401-13. PubMed: 21805181

PAPER Pallebage-Gamarallage MM, Galloway S, Takechi R, Dhaliwal S, Mamo JC

Probucol Suppresses Enterocytic Accumulation of Amyloid-β Induced by Saturated Fat and Cholesterol Feeding.

Lipids. 2012 Jan;47(1):27-34. PubMed: 21805327

PAPER Yata K, Oikawa S, Sasaki R, Shindo A, Yang R, Murata M, Kanamaru K, Tomimoto H

Astrocytic neuroprotection through induction of cytoprotective molecules; a proteomic analysis of mutant P301S tau-transgenic mouse.

Brain Res. 2011 Sep 2;1410:12-23. PubMed: 21803337

PAPER

AD diagnostic guidelines updated.

Endocr Rev. 2011 Aug;32(4):532-49. PubMed: 21622890

PAPER Shand JA, Howe A

Differentiating Alzheimers dementia from dementia with Lewy bodies remains challenging.

Biomark Med. 2011 Jun;5(3):373. PubMed: 21800462

PAPER Schulz I, Engel C, Niestroj AJ, Zeitschel U, Menge K, Kehlen A, Meyer A, Rossner S, Demuth HU

Heteroarylketones inhibit astroglial interleukin-6 expression via a STAT3/NF-κB signaling pathway.

J Neuroinflammation. 2011;8:86. PubMed: 21801384

PAPER Rapoport SI, Nelson PT

Biomarkers and evolution in Alzheimer disease.

Prog Neurobiol. 2011 Dec;95(4):510-3. PubMed: 21801803

PAPER Hara H, Mouri A, Yonemitsu Y, Nabeshima T, Tabira T

Mucosal immunotherapy in an Alzheimer mouse model by recombinant Sendai virus vector carrying Aβ1-43/IL-10 cDNA.

Vaccine. 2011 Oct 6;29(43):7474-82. PubMed: 21803105

PAPER Royall DR, Palmer RF, Petrovitch H, Ross GW, Masaki K, White LR

Modeling regional vulnerability to Alzheimer pathology.

Neurobiol Aging. 2011 Jul 29; PubMed: 21803455

PAPER Molinuevo JL, Hernández B,

[Profile of the informal carer associated with the clinical management of the Alzheimer's disease patient refractory to symptomatic treatment of the disease].

Neurologia. 2011 Nov;26(9):518-27. PubMed: 21803459

PAPER Shimazawa R, Ikeda M

Delays in neurological drug development in Japan.

Intern Med. 2011;50(15):1565-8. PubMed: 21804282

PAPER Koedam EL, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YA, Fox N, Barkhof F, Wattjes MP

Visual assessment of posterior atrophy development of a MRI rating scale.

Eur Radiol. 2011 Dec;21(12):2618-25. PubMed: 21805370

PAPER Paige JS, Wu KY, Jaffrey SR

RNA mimics of green fluorescent protein.

Science. 2011 Jul 29;333(6042):642-6. PubMed: 21798953

William Rodman Shankle on Paris: More Trial News, Mixed at Best

COMMENT I'd like to expand on Bonetta's coverage of our work. The implication of our presentation on IVIG is that IVIG therapy may delay progression of more than just AD. The most parsimonious explanation for a disease-modifying effect of IVIG in both A